Catalyst Pharmaceuticals, Inc. (CPRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Catalyst Pharmaceuticals, Inc. (CPRX) is up 34.0% since the beginning of the year. At $31 per share, CPRX is trading 3.9% below its 52-week high of $33. Investors who bought $1,000 worth of CPRX shares 5 years ago would now be looking at an investment worth $5,709.

Catalyst Pharmaceuticals, Inc. (CPRX) has returned 34.02% so far this year and 25.57% over the past 12 months. Looking at the last ten years, CPRX has achieved an annualized return of 48.24%, outperforming the S&P 500 Index benchmark, which averaged 13.66% per year.

Based on dividend-adjusted daily data since Nov 8, 2006, CPRX's average daily return is +0.20%, while the average monthly return is +3.55%. At this rate, an investment would double in approximately 1.7 years.

Historically, 54% of months were positive and 46% were negative. The best month was Aug 2009 with a return of +239.1%, while the worst month was Nov 2012 at -67.2%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.

On a daily basis, CPRX closed higher 46% of trading days. The best single day was Aug 31, 2009 with a return of +201.8%, while the worst single day was Nov 8, 2012 at -65.5%.

Catalyst Pharmaceuticals, Inc. has an annualized alpha of 51.13%, beta of 0.82, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 09, 2006.

• This stock participated in 80.06% of S&P 500 Index downside but only 79.99% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CPRX ranks 60 for risk / return — better than 60% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Catalyst Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Catalyst Pharmaceuticals, Inc. was 94.25%, occurring on Nov 12, 2012. Recovery took 1717 trading sessions.

The current Catalyst Pharmaceuticals, Inc. drawdown is 0.16%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Catalyst Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Catalyst Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.